Third Wave CEO applauds FDA on updated drug labeling
Third Wave Technologies is just fine with a recent Food and Drug Administration announcement on relabeling for the blood thinning drugs Coumadin and Wafarin, which have been linked to adverse drug reactions in emergency room settings. The Madison biotechnology company soon will provide an update...